Use of adipose tissue-derived stromal stem cells in treating fistula

Abstract

Provided herein are novel methods and compositions utilizing adipose tissue-derived stromal stem cells for treating fistulae.

1 - 35 . (canceled) 
     
     
         36 . A method of preparing an adhesive for fistula repair, comprising suspending an adipose tissue-derived stromal stem cell-containing composition, wherein at least about 50% of the adipose tissue-derived stromal stem cells comprising the composition express the CD9, CD10, CD13, CD29, CD44, CD49A, CD51, CD54, CD55, CD58, CD59, CD90 and CD105 markers with a fibrin-based polymer. 
     
     
         37 . A method of treating a fistula in a subject, comprising: (a) closing the internal hole with a suture and (b) delivering at least about 10×10 6  adipose tissue-derived stromal stem cells and a fibrin-based polymer to the closed sutured internal hole. 
     
     
         38 . The method of  claim 37 , wherein the adipose tissue-derived stromal stem cells comprise an adipose tissue-derived stromal stem cell-containing composition wherein at least about 50% of the adipose tissue-derived stromal stem cells comprising the composition express the CD9, CD10, CD13, CD29, CD44, CD49A, CD51, CD54, CD55, CD58, CD59, CD90 and CD105 markers. 
     
     
         39 . The method of  claim 37 , further comprising: (c) deep scraping of at least one fistula track. 
     
     
         40 . The method of  claim 37 , wherein said fibrin based polymer is a fibrin glue or gel. 
     
     
         41 . The method of  claim 37 , wherein said method further comprises: (c) delivering a second dose of at least about 20×10 6  adipose tissue-derived stromal stem cells. 
     
     
         42 . The method of  claim 37 , wherein said method comprises delivering at least about 20×10 6  adipose tissue-derived stromal stem cells. 
     
     
         43 . The method of  claim 42 , wherein said method further comprises: (c) delivering a second dose of at least about 40×10 6  adipose tissue-derived stromal stem cells. 
     
     
         44 . The method of  claim 37 , wherein the adipose tissue-derived stromal stem cells are derived from the adipose tissue of the subject. 
     
     
         45 . The method of  claim 37 , wherein the fistula is an anorectal, enteroenteral, enterocutaneous, rectovaginal or vesicovaginal fistula. 
     
     
         46 . The method of  claim 37 , further comprising administering a therapeutic agent to said subject. 
     
     
         47 . The method of  claim 46 , wherein said therapeutic agent is administered locally to the closed sutured internal hole. 
     
     
         48 . The method of  claim 47 , wherein said therapeutic agent is administered systemically to said subject. 
     
     
         49 . A method of treating a wound in a subject, comprising: (a) closing the wound with a suture and (b) delivering at least about 10×10 6  adipose tissue-derived stromal stem cells and a fibrin-based polymer to the closed sutured wound. 
     
     
         50 . The method of  claim 49 , wherein the adipose tissue-derived stromal stem cells comprise a cellular composition, wherein at least about 50% of the adipose tissue-derived stromal stem cells comprising the composition express the CD9, CD10, CD13, CD29, CD44, CD49A, CD51, CD54, CD55, CD58, CD59, CD90 and CD105 markers. 
     
     
         51 . A method of  claim 36 , wherein the stem cells are allogeneic. 
     
     
         52 . A method of  claim 37 , wherein the stem cells are allogeneic. 
     
     
         53 . A method of  claim 49 , wherein the stem cells are allogeneic.